Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of probiotic Escherichia coli Nissle 1917 to prevent gram-negative gastric colonization in ventilated ICU patients
2011-002343-99Phase 2Completed
- Sponsor
- Heart of England NHS Foundation Trust
- Start
- Sep 2011
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of escherichia coli nissle 1917 in Gastric colonization by pathogenic gram-negative bacteria and ventilator-associated pneumonia (VAP) (2 arms), sponsored by Heart of England NHS Foundation Trust. Primary endpoint: Successful gastric colonization by Escherichia coli Nissle 1917. Started Sep 2011; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
Gastric colonization by pathogenic gram-negative bacteriaventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2011-002343-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002343-99.